CD19 and hepatocellular carcinoma: This is one of the main reasons why CAR-T is more effective than solid tumors in the treatment of hematological malignancies, etc. Hematologic and lymphoid cancers have specific tumor antigens, e.g., CD13, CD33 for acute promyelocytic leukemia, CD19 for diffuse large B cell lymphoma, etc. Antigens commonly expressed in hepatocellular carcinoma, such as GPC3 and AFP, vary greatly in the amount and type of expression among individuals with HCC.